ClinicalTrials.gg
CompletedNCT06605547Updated Sep 23, 2024

The Effect of I-PRF As An Adjunct to Non-Surgical Periodontal Therapy on Clinical Parameters in Smokers With Periodontitis

An interventional study of Non-surgical periodontal treatment and Subgingival application of saline in Periodontitis, sponsored by Abant Izzet Baysal University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-09-23.

Sponsored by Abant Izzet Baysal University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Sep 2023, registered Sep 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Study summary

The aim of this clinical trial is to evaluate the effect of subgingival injectable platelet-rich fibrin (i-PRF) application on clinical periodontal parameters as an adjunct to non-surgical periodontal treatment (NSPT) in smokers with periodontitis.

Twenty-five systemically healthy, smoker patients with stage II/III periodontitis were included in the study. In this split-mouth trial, subgingival i-PRF was applied to the test group in addition to NSPT, while saline was applied to the control group after NSPT. Subgingival i-PRF/saline application was repeated on the 7th day in both groups. Clinical periodontal parameters were recorded at baseline, 1st and 3rd months after the treatment.

Read the detailed description

Twenty-five systemically healthy, smoker patients with periodontitis were included in the study. All individuals were examined at baseline, 1st and 3rd months after non-surgical periodontal treatment including, whole mouth probing pocket depth (PPD), clinical attachment loss (CAL), presence of bleeding on probing (BOP), gingival index (GI) and Turesky Modified Quigley-Hein Plaque Index (TQHPI) except the third molars. PPD and CAL were measured at six sites per tooth using a manual periodontal probe. All measurements and NSPT were performed by the same blinded and calibrated examiner (TCG).

The NSPT included supra- and subgingival scaling, root planing and oral hygiene instructions. Subgingival scaling and root planing were performed under local anesthesia within the 24 h. After NSPT, four contralateral deep pockets (two for each side) in premolar/molar ares were determined. The sites were randomly divided into test sites receiving the subgingival application of i-PRF and controls treated with saline.

After the NSPT was completed, the i-PRF was produced as follows: 9 mL of whole blood was collected from the antecubital vein in a sterile plastic tubes without anticoagulant and immediately centrifuged at 700 rpm for 3 minutes with a centrifuge device. After centrifugation, the upper liquid layer was collected as i-PRF and placed into an insulin syringe connected to a 29G needle.

Before the i-PRF application, the teeth were isolated with a cotton roll and dried with a cotton pellet. The 29-gauge needle tip was gently placed into the periodontal pocket and the i-PRF was injected into the periodontal pocket until it reached the gingival margin (until it overflowed from the sulcus). For the subgingival saline application, the insulin syringe was filled with saline and the 29-gauge needle tip was gently placed into the periodontal pocket. The saline was injected into the periodontal pocket until it was seen to overflow from the gingival margin. After the subgingival application of i-PRF/saline , the application areas were isolated and waited for 10 minutes in order to prevent the i-PRF from being removed from the sulcus with oral fluids until it turned into a gel. Subgingival i-PRF/salin application was performed by a periodontist (BMY).Patients were instructed not to drink or eat anything, including water, for at least 30 minutes after the procedure. Patients were informed about oral hygiene practices (tooth brushing and interdental cleaning) and were motivated to perform daily oral care. Patients were given an appointment for the second application of i-PRF/salin application 7 days later. In this session, i-PRF/salin application was applied to the previously applied areas, oral hygiene was checked and patients were informed again. Patients were called again in the 1st and 3rd months, periodontal clinical measurements were repeated and oral hygiene motivation was given.

Statistical analyses were performed using a statistical analysis software (SPSS v.25.0; IBM). The Shapiro Wilk test was used to determine the normality of the present data and the variance homogeneity was checked with the Levene test. For non-normally distributed data, the Mann Whitney U test was used for pairwise comparison. The Independent Samples T test was performed for normally distributed data. The Friedman test was used to examine the differences between three dependent groups. Bonferroni correction was performed for multiple variations. The statistical significance value was accepted as p \< 0.05.

02

Conditions studied

  • Periodontitis

Browse trials for

Keywords

  • smoker
  • periodontitis
  • i-PRF
03

In context

Periodontitis

1,664 studies on the registry are indexed under Periodontitis; 328 are open to participants now.

This study's enrollment of 25 is below the median of 45 across 1,206 interventional studies indexed under Periodontitis.

Browse Periodontitis studies →

Lead sponsor

Abant Izzet Baysal University is the lead sponsor of 247 studies on the registry; 64 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients were systemically healthy adults,
  • having at least 20 natural teeth,
  • the presence of contralateral periodontal pockets (PPD≥ 5 mm) and CAL≥2 mm on a minimum of two premolar/molar teeth on each side and no furcation involvement,
  • smoking more than 10 cigarettes per day for at least 5 years,
  • stage II-III periodontitis patients

Exclusion criteria

Exclusion Criteria:

  • individuals had past periodontal treatment within 6 months
  • individuals had used systemic antibiotics in the last 6 months or anti- inflammatory drugs in the last 3 months before the beginning of the trial,
  • patient with clotting and hematologic disorders, had used drugs affecting the natural coagulation process,
  • patients taking medications that affect the gingival and periodontal tissues
  • pregnant or breastfeeding females
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
25 participants (actual)

Study arms

  • Active comparator
    Test group

    Test sites receiving the subgingival application of i-PRF after NSPT.

    Procedure: Non-surgical periodontal treatment · Other: Subgingival application of i-PRF

  • Placebo comparator
    Control group

    Control sites treated with saline after NSPT.

    Procedure: Non-surgical periodontal treatment · Device: Subgingival application of saline

Interventions

  • ProcedureNon-surgical periodontal treatment

    The non-surgical periodontal treatment (scaling and root planing) was applied under local anesthesia using ultrasonic device and Gracey curettes. After scaling and root planing, periodontal pockets were irrigated using saline solution. Non-surgical periodontal treatment was completed in one or two sessions within 24 hours.

  • DeviceSubgingival application of saline

    For the subgingival saline application at the control sites, the insulin needle was filled with saline and the 29-gauge needle tip was gently placed into the periodontal pocket. The saline was injected into the periodontal pocket until it was seen to overflow from the gingival margin. Subgingival saline application was repeated on the 7th day.

  • OtherSubgingival application of i-PRF

    For subgingival application of i-PRF at the test sites, the i-PRF taken into the insulin syringe, the 29-gauge needle tip was gently placed into the periodontal pocket and the i-PRF was injected into the periodontal pocket until it reached the gingival margin (until it overflowed from the sulcus). Subgingival i-PRF application was repeated on the 7th day.

06

What researchers measure

Primary outcomes

  1. Clinical attachment loss (CAL)

    CAL measured as the change in distance from the cementoenamel junction to the bottom of the gingival sulcus (the most coronal attachment) using a Williams periodontal probe. The changes in clinical attachment loss was measured for determining the severity of disease.

    Time frame: Baseline, 1st and 3rd months

  2. Probing pocket depth (PPD)

    PPD measured as the change in distance from the gingival margin to the bottom of the gingival sulcus using a Williams periodontal probe. The changes in PPD was measured for determining of the severity of disease and clinical outcome.

    Time frame: Baseline, 1st and 3rd months

Secondary outcomes

  1. Bleeding on probing (BOP)

    All six sites of all teeth were probed to assess whether this elicited bleeding (+) or not (-). The severity of gingival inflammation was expressed as a percentage (BOP=number of bleeding sites×100/number of sites evaluated). Bleeding on probing was recorded for classifying and evaluating gingival inflammation

    Time frame: Baseline, 1st and 3rd months

  2. Turesky Modified Quigley-Hein Plaque Index (TQHPI)

    TQHPI for the entire mouth was determined by dividing the total score by the number of surfaces examined. Scoring was as follows: * 0: no plaque * 1: separate flecks of plaque at the cervical margin of the tooth * 2: a thin continuous band of plaque (≤ 1 mm) at the cervical margin of the tooth * 3: a band of plaque \> 1 mm but covering less than one-third of the crown of the tooth * 4: plaque covering at least one-third but less than two- thirds of the crown of the tooth * 5: plaque covering two-thirds or more of the crown of the tooth labial/buccal and lingual surfaces assessed after using a disclosing solution. TQHPI was recorded for determining and classifying oral hygiene status.

    Time frame: Baseline, 1st and 3rd months

  3. Gingival index (GI)

    To determine the gingival index (Löe \& Silness), gingival bleeding caused by running a Williams periodontal probe inside the pocket on the mesial, distal, buccal, and palatal surfaces of all teeth was evaluated. The gingival index of an individual was obtained by summing the values determined for each tooth and calculating the averages. Scoring was as follows: * 0: Healthy gums. * 1: Mild discolouration and oedematous gingiva. No bleeding on probing. * 2: Red, oedematous and shiny gingiva. There is bleeding on probing. * 3: Red, oedematous and ulcerated gingiva. There is spontaneous bleeding. Gingival index was recorded for classifying and evaluating sulcular gingival inflammation.

    Time frame: Baseline, 1st and 3rd months

07

Study locations

1 site
  • Bolu Abant Izzet Baysal University
    Bolu, 14030, Turkey (Türkiye)
08

References and documents

Publications

  • Cagiran Gurbuz T, Meraci Yildiran B. The clinical efficacy of injectable platelet-rich fibrin (i-PRF) as an adjunct to nonsurgical periodontal therapy in smokers with periodontitis. BMC Oral Health. 2025 Apr 23;25(1):618. doi: 10.1186/s12903-025-06019-w. PubMed 40269777 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06605547
Responsible party
Bilge MERACI YILDIRAN (Assistant Professor, Abant Izzet Baysal University) — Principal investigator
First posted
Sep 20, 2024
Start date
Sep 4, 2023
Primary completion
Apr 30, 2024
Completion
Apr 30, 2024
Last update
Sep 23, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion